EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Selective Estrogen Receptor β (SERβ) Agonist ( S )-STO021 as an Antiosteoporosis Candidate with Dual Functions of Inhibiting Osteoclastogenesis and Activating Osteoblastogenesis

Cheng Peng, Zixiang Geng, Zhe Jiang, Jin-Feng Ning, Nan Wang, Chen Zhong, Yongfang Zhao, Xun Sun iD, Mei-Lin Tang iD

Journal of Medicinal Chemistry · 13.11.2025 · 68 (21) · 22715-22737

DOI: 10.1021/acs.jmedchem.5c01697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.10.2025. Verfasst von Cheng Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Natural Medicine, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. Hauptthemen laut MEDLINE: Estrogen Receptor beta, Osteoporosis, Osteoclasts, Osteoblasts. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Science and Technology Commission of Shanghai Municipality, Shanghai Central Guidance for Local Science and Technology Development Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis is a systemic and chronic metabolic bone disease of high fracture and mortality. Simultaneous regulation of osteoblast-mediated bone formation and osteoclast-mediated bone resorption has become a potentially effective therapeutic strategy to overcome osteoporosis. Recently, selective activation of estrogen receptor β (SERβ) was demonstrated to promote osteoblast formation and inhibit osteoclast absorption, suggesting that SERβ agonists may be another promising therapeutic approach for treating osteoporosis. Herein, we reported the discovery of a bisphosphonate indanone compound (S)-STO021 as a novel SERβ agonist, which exhibited excellent dual functional effects of inhibiting osteoclast resorption and promoting osteoblast formation. Mechanically, the antiosteoporosis efficacy of (S)-STO021 was achieved through inhibiting the TAK1/MKK6/p38 signal and promoting the ERβ/BMP4/SMAD signal. Furthermore, (S)-STO021 could not only effectively improve the zebrafish osteoporosis model induced by glucocorticoids but also greatly restore the bone microstructure in ovariectomized rat models. Collectively, our SERβ agonist (S)-STO021 could regulate osteoblast and osteoclast differentiation, showing the potential to treat osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor betaOsteoporosisOsteoclastsOsteoblastsOsteogenesisDiphosphonatesAnimalsZebrafishRatsHumansMiceFemaleRats, Sprague-DawleyCell DifferentiationDrug DiscoveryStructure-Activity RelationshipRAW 264.7 Cells

Substanzen

Estrogen Receptor betaDiphosphonates

Autor:innen und Institutionen

  • Department of Natural Medicine, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.
  • Shi's Center of Orthopedics and Traumatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • The Institutes of Integrative Medicine of Fudan University, 12 Wulumuqi Zhong Road, Shanghai 200040, China.
  • Shanghai Pudong Hospital, Pharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai 201203, China.

ORCID-Profile: Xun Sun, Mei-Lin Tang

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Central Guidance for Local Science and Technology Development Fund Project

Zitieren

APA

Peng, C., Geng, Z., Jiang, Z., Ning, J. F., Wang, N., Zhong, C., Zhao, Y., Sun, X., & Tang, M. L. (2025). Discovery of Novel Selective Estrogen Receptor β (SERβ) Agonist ( S )-STO021 as an Antiosteoporosis Candidate with Dual Functions of Inhibiting Osteoclastogenesis and Activating Osteoblastogenesis. Journal of Medicinal Chemistry, 68(21), 22715-22737. https://doi.org/10.1021/acs.jmedchem.5c01697

Vancouver

Peng C, Geng Z, Jiang Z, Ning JF, Wang N, Zhong C, et al. Discovery of Novel Selective Estrogen Receptor β (SERβ) Agonist ( S )-STO021 as an Antiosteoporosis Candidate with Dual Functions of Inhibiting Osteoclastogenesis and Activating Osteoblastogenesis. Journal of Medicinal Chemistry. 2025;68(21):22715-22737. doi:10.1021/acs.jmedchem.5c01697

BibTeX
@article{Peng2025,
  author = {Peng, Cheng and Geng, Zixiang and Jiang, Zhe and Ning, Jin-Feng and Wang, Nan and Zhong, Chen and Zhao, Yongfang and Sun, Xun and Tang, Mei-Lin},
  title = {Discovery of Novel Selective Estrogen Receptor β (SERβ) Agonist ( S )-STO021 as an Antiosteoporosis Candidate with Dual Functions of Inhibiting Osteoclastogenesis and Activating Osteoblastogenesis},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {21},
  pages = {22715--22737},
  doi = {10.1021/acs.jmedchem.5c01697}
}
Kostenlos starten →